Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application
Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Novel NK cell Therapeutics ZM008 Against Locally Advanced or Metastatic Solid Tumors - FDA provides very specific [...]
Abrogation of natural killer cell check point pathway LLT1/CD161 by novel anti LLT1 antibody ZM008 and its therapeutic applications in solid cancers.
Maloy Ghosh, Sanghamitra Bhattacharjee, Anurag Tiwari, Ashvini Kumar Dubey, Yogendra Manjunath, Pallavi Lahiri, Amir Horowitz; Zumutor Biologics, Bangalore, India; Precision Immunology Institute/Tisch Cancer Institute, Icahn School of Medicine at [...]
INABLRS® – End to end antibody discovery platform
Major strategies for mining human antibody repertoires are: a) non-combinatorial and b) combinatorial strategies. Non-combinatorial strategies retrieve human Monoclonal Antibodies (mAbs) from single B-cells with the original heavy and [...]